Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies

Tavitian, Suzanne; Péron, Jean‐Marie; Huguet, Françoise; Kamar, Nassim; Abravanel, Florence; Beyne‐Rauzy, Odile; Obéric, Lucie; Faguer, Stanislas; Alric, Laurent; Roussel, Murielle; Gaudin, C.; Ysebaert, Loïc; Huynh, Anne; Récher, Christian

doi:10.3201/eid2108.150199

Cited by 42 publications

(55 citation statements)

References 13 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunocompromised patients in Europe include HIV-infected patients [111–115], solid-organ transplant (SOT) recipients [15, 19, 116–126], and individuals under immunosuppressive therapy or with hematological diseases [126–131]. Chronic hepatitis E is caused by genotype 3 strains [9], although one recently described case has been associated with genotype 4 [132].…”

Section: Acute and Chronic Hepatitis Ementioning

confidence: 99%

“…Chronic hepatitis E is caused by genotype 3 strains [9], although one recently described case has been associated with genotype 4 [132]. According to some authors, the reduction of immunosuppressive therapy (if possible) or treatments with ribavirin or pegylated-interferon plus ribavirin may induce the clearance of the virus [15, 114, 125, 131]. In Spain, one chronic HEV infection was identified in an immunocompetent man as reported by Gonzalez Tallon et al [133].…”

Section: Acute and Chronic Hepatitis Ementioning

confidence: 99%

See 1 more Smart Citation

Hepatitis E Virus in Industrialized Countries: The Silent Threat

Clemente-Casares

Ramos-Romero

Ramirez-Gonzalez

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

Hepatitis E virus (HEV) is the main cause of acute viral hepatitis worldwide. Its presence in developing countries has been documented for decades. Developed countries were supposed to be virus-free and initially only imported cases were detected in those areas. However, sporadic and autochthonous cases of HEV infection have been identified and studies reveal that the virus is worldwide spread. Chronic hepatitis and multiple extrahepatic manifestations have also been associated with HEV. We review the data from European countries, where human, animal, and environmental data have been collected since the 90s. In Europe, autochthonous HEV strains were first detected in the late 90s and early 2000s. Since then, serological data have shown that the virus infects quite frequently the European population and that some species, such as pigs, wild boars, and deer, are reservoirs. HEV strains can be isolated from environmental samples and reach the food chain, as shown by the detection of the virus in mussels and in contaminated pork products as sausages or meat. All these data highlight the need of studies directed to control the sources of HEV to protect immunocompromised individuals that seem the weakest link of the HEV epidemiology in industrialized regions.

show abstract

Section: Acute and Chronic Hepatitis Ementioning

confidence: 99%

Section: Acute and Chronic Hepatitis Ementioning

confidence: 99%

Hepatitis E Virus in Industrialized Countries: The Silent Threat

Clemente-Casares

Ramos-Romero

Ramirez-Gonzalez

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…These patients may experience viral clearance over time and the return of immunity. This may induce a rebound in cytolysis and severe acute hepatitis …”

Section: Chronic Hepatitismentioning

confidence: 99%

“…Chronic or persistent hepatitis in patients with HIV or receiving chemotherapy for haematological malignancies can be treated with ribavirin in the same manner …”

Section: Treatment and Preventionmentioning

confidence: 99%

Hepatitis E, what’s the real issue?

Larrue

Abravanel

Péron

2020

Liver International

Self Cite

View full text Add to dashboard Cite

Hepatitis E Virus (HEV) infection is a worldwide disease and the primary cause of acute viral hepatitis in the world with an estimated 20 million cases every year and 70 000 deaths. Hepatitis E is a waterborne infection in the developing countries. In these countries, HEV genotypes 1 and 2 cause large outbreaks and affect young subjects, resulting in significant mortality in pregnant women and patients with cirrhosis. In the developed countries, HEV genotypes 3 and 4 are responsible for autochthonous, sporadic hepatitis and transmission is zoonotic. Parenteral transmission by the transfusion of blood products has been identified as a potential new mode of transmission. The prevalence of positive HEV viraemia in blood donors in Europe ranges from 1/600 to 1/2500 in highly endemic European countries. HEV can cause neurological disorders and chronic infections in immunocompromised patients. The progression of acute hepatitis E is usually asymptomatic and resolves spontaneously. Diagnostic tools include anti‐HEV IgM antibodies in serum and/or viral RNA detection in the blood or the stools by PCR. Ribavirin is used to treat chronic infection. A vaccine has been developed in China.

show abstract

“…Chronic hepatitis E has also been described in patients with haematological malignancies . They are also usually asymptomatic.…”

Section: Chronic Hepatitismentioning

confidence: 99%

Hepatitis E, the neglected one

Blasco-Perrin

Abravanel

Blasco-Baqué

et al. 2016

Liver International

Self Cite

View full text Add to dashboard Cite

Hepatitis E virus (HEV) infection is a worldwide disease. It is the first cause of acute viral hepatitis in the world with an estimated 20 million cases every year and 56 000 deaths. In developing countries, hepatitis E is a waterborne infection. In these countries, HEV genotypes 1 and 2 cause large outbreaks and affect young subjects with a significant mortality rate in pregnant women and patients with cirrhosis. In the developed countries, HEV genotypes 3 and 4 are responsible for autochthonous, sporadic hepatitis and transmission is zoonotic. HEV can cause neurological disorders and in immunocompromised patients, chronic infections. The progression of acute hepatitis E is most often mild and resolves spontaneously. Diagnostic tools include anti-HEV IgM antibodies in serum and/or viral RNA in the blood or stools by PCR. Ribavirin is used to treat chronic infection. A vaccine has been developed in China. Keywords acute viral hepatitis -chronic hepatitis -hepatitis E virus -neurological symptoms -ribavirin -zoonosisHepatitis E virus (HEV) was discovered by immune electron microscopy in 1983 by Dr. Balayan, who was investigating an outbreak of unexplained hepatitis in Russian soldiers stationed in Afghanistan (1). The hepatitis E genome was sequenced in 1991. The same year, a test was developed for detecting anti-HEV antibodies (2). The purpose of this paper is to review the virology, epidemiology, clinical aspects and treatment of hepatitis E. Background and virology

show abstract

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies

Cited by 42 publications

References 13 publications

Hepatitis E Virus in Industrialized Countries: The Silent Threat

Hepatitis E Virus in Industrialized Countries: The Silent Threat

Hepatitis E, what’s the real issue?

Hepatitis E, the neglected one

Contact Info

Product

Resources

About